FDA Sets Date For Resubmitted Dupixent in Inflammatory Skin Disease
The FDA has accepted the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric...
Resubmitted
The FDA has accepted the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric...
